Glonghui, January 10, 丨 Morgan Stanley published a report on China's capital market strategy, stating that it is optimistic about the prospects of the MSCI China Index and its “increase” rating for the Chinese market, and raised the “basic scenario” forecast target for the Hang Seng Index until December this year, from 21,200 points to 24,500 points; the National Index rose from 7,400 points to 8,250 points; the Shanghai and Shenzhen 300 Index rose from 4,350 points to 4,500 points, which is equivalent to predicting a market rate of 12.1 times. The bank suggests buying themed stocks benefiting from the reopening of China's economy, and is expected to suggest “increasing” China's holdings in global/emerging market stock portfolios because it believes China will perform well in 2023. Damo also listed a list of “re-customs clearance” themed stocks benefiting from China, including BZ.US, Anta (2020.HK), Ctrip (TCOM.US), Yum China (YUMC.US), Li Ning (2331.HK), Zhongsheng (0881.HK), Xinxiuli (1910.HK), Taobo (6110.HK), Xinxiuli (1910.HK), Fushouyuan (1448.HK), Wuliangye (000858.SZ) Wei Asia Pacific (1876.HK), China Resources Beer (0291.HK), Pharmaceutical Kangde (2359.HK), Pharmaceutical Biology (2269.HK), Tiger Pharmaceuticals (300347.SZ), Tongrentang Sinopharm (3613.HK), Cathay Pacific (0293.HK), Bank of China Aviation Leasing (2588.HK), Taikoo A (0019.HK) and Xishen (0014.HK).